Holen Sie sich die Stockscreener-App
5.90
0.34%
-0.02
Handel nachbörslich:
5.90
Revance Therapeutics Inc Aktie (RVNC) Neueste Nachrichten
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders - GlobeNewswire Inc.
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in September - MarketBeat
AQR Capital Management LLC Has $517,000 Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Algert Global LLC Sells 127,260 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com - MarketBeat
(RVNC) Investment Report - Stock Traders Daily
Revance Therapeutics, Crown Labs tender offer extended until Oct. 18 - MSN
Renaissance Technologies LLC Acquires 198,300 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics extends tender offer amid Teoxane dispute - Investing.com
Revance Therapeutics merger delayed due to alleged contract breach - The Business Journals
Revance Therapeutics (NASDAQ:RVNC) Shares Down 4.6%Should You Sell? - MarketBeat
William Blair Downgrades Revance Therapeutics (RVNC) - MSN
Revance Therapeutics extends tender offer amid Teoxane dispute By Investing.com - Investing.com UK
Revance Therapeutics, Crown Labs Extend Tender Offer Start Deadline to Oct. 18 >RVNC - MarketWatch
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Gap Down to $5.36 - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) is Stonepine Capital Management LLC's 5th Largest Position - MarketBeat
Revance Therapeutics' SWOT analysis: tender offer shakes up aesthetics stock - Investing.com
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround - MSN
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Malaysian Reserve
Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares (RVNC) - Seeking Alpha
When (RVNC) Moves Investors should Listen - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, GATO, RFL on Behalf of Shareholders - Longview News-Journal
1.11%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):